| Literature DB >> 35482756 |
Yadeta Babu Beyene1, Fekede Bekele Daba2, Kabaye Kumela Goro2, Birbirsa Sefera Senbeta1.
Abstract
BACKGROUND: The care of epileptic patients is complicated by the cognitive adverse effect of the drug, disease, pharmacokinetics, and pharmacodynamics properties of antiepileptic drugs which in turn intensify the risk of drug therapy problems among epileptic patients.Entities:
Mesh:
Year: 2022 PMID: 35482756 PMCID: PMC9049505 DOI: 10.1371/journal.pone.0267673
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.752
Socio-demographic and behavioral related characteristics of epileptic patients attending the ambulatory clinic of JMC, 2021.
| Characteristics | Frequency (n) | Percentage (%) |
|---|---|---|
| Mean (±SD) age | 29.9 ±11.2 | |
| Age in years | ||
| 18–25 | 149 | 46.6 |
| 26–44 | 132 | 41.3 |
| ≥45 | 39 | 12.2 |
| Gender | ||
| Male | 176 | 55 |
| Female | 144 | 45 |
| Residency | ||
| Urban | 150 | 46.1 |
| Rural | 170 | 53.1 |
| Monthly income | ||
| No regular income | 287 | 89.7 |
| Regular income | 33 | 10.31 |
| Educational status | ||
| Un educated | 90 | 28.1 |
| Educated | 230 | 71.9 |
| Occupation | ||
| Farmer | 87 | 27.2 |
| Student | 60 | 18.8 |
| Daily laborer | 29 | 9.1 |
| Employed | 22 | 6.9 |
| Merchant | 14 | 4.4 |
| Housewife | 36 | 11.3 |
| Jobless | 72 | 22.5 |
| Religion | ||
| Orthodox | 77 | 24.1 |
| Muslim | 218 | 68.1 |
| Protestant | 20 | 6.3 |
| Catholic | 5 | 1.6 |
| Living condition | ||
| Living alone | 22 | 6.9 |
| With family | 298 | 93.1 |
| How to get medication | ||
| Free | 188 | 58.75 |
| Payment | 132 | 41.25 |
| Social drug-using status | ||
| Yes | 64 | 20 |
| No | 256 | 80 |
| Patient involvement | ||
| Actively involved | 117 | 36.56 |
| Poorly involved | 203 | 63.43 |
Clinical characteristics of epileptic patients attending ambulatory clinic of JMC, 2021.
| Clinical characteristics | Frequency (n) | Percentage (%) |
|---|---|---|
| Types of seizure | ||
| GTC | 221 | 69.1 |
| Focal | 25 | 7.8 |
| Unclassified* | 74 | 23.1 |
| Follow-up duration | ||
| 1–5 years | 80 | 25 |
| 6–10 years | 78 | 24.4 |
| >10 years | 162 | 50.6 |
| Seizure control status | ||
| Controlled | 168 | 52.5 |
| Uncontrolled | 152 | 47.5 |
| Comorbidity | ||
| Yes | 69 | 21.6 |
| No | 251 | 78.4 |
| Comorbid condition | ||
| Dyspepsia | 19 | 5.9 |
| Hypertension | 15 | 4.6 |
| Schizophrenia | 7 | 2.2 |
| PNP | 5 | 1.5 |
| RVI | 4 | 1.3 |
| DM | 4 | 1.3 |
| Hemorrhoid | 4 | 1.3 |
| Back pain | 3 | 0.9 |
| Stroke | 3 | 0.9 |
| Othersa | 5 | 1.5 |
PNP: Peripheral neuropathy, RVI: Retroviral Infection, DM: Diabetic Mellitus, GTC: Generalized tonic-clonic, Unclassified*: documented diagnosis as epilepsy disorder without any classification, Othersa: Ischemic heart disease, Sexual dysfunction, Tinea pedis, Migraine headache.
Medication use pattern of epileptic patients attending ambulatory clinic of JUMC, 2021.
| Variables | Frequency (n) | Percentage (%) |
|---|---|---|
| Number of AED | ||
| One | 162 | 50.6 |
| Two | 142 | 44.3 |
| Three | 16 | 5 |
| AED use pattern | ||
| PB | 117 | 36.5 |
| PHT | 39 | 12.2 |
| VPA | 4 | 1.3 |
| CBZ | 2 | 0.6 |
| PB+PHT | 107 | 33.4 |
| PB+CBZ | 25 | 7.8 |
| PB+VPA | 3 | 0.9 |
| PHT+CBZ | 4 | 1.3 |
| PHT+VPA | 3 | 0.9 |
| PB+PHT+CBZ | 11 | 3.4 |
| PB+PHT+VPA | 3 | 0.9 |
| PHT+CBZ+VPA | 2 | 0.6 |
| Total drugs per patient | ||
| One drug | 137 | 42.8 |
| Two drugs | 133 | 41.56 |
| Three drugs &above | 50 | 15.6 |
PHB: phenobarbital, PHT: phenytoin, CBZ: carbamazepine, VPA: Valproic acid.
Types and cause of DTP among epileptic patients at the ambulatory clinic of JMC, 2021.
| DTP category and causes | Proportion of DTP, n = 395 |
|---|---|
|
|
|
| Does not understand the instruction | 2(1.7) |
| Prefer not to take the medication | 11(9.6) |
| The drug product is too expensive for the patient | 33(28.7) |
| Forgets to take medication | 39(33.9) |
| The drug product is not available for the patient | 30(26.1) |
|
|
|
| The drug product causes an undesirable reaction that is not dose-related | 97(88.2) |
| A safer drug product is required due to risk factors | 7(6.4) |
| The drug product is contraindicated due to risk factors | 6(5.4) |
|
|
|
| Th | 64(62.1) |
| A drug interaction reduces the amount of active drugs available | 39(37.8) |
|
|
|
| The dose is too high | 44(80) |
| The duration of drug therapy is long for a given condition | 6(10.9) |
| Drug interaction |
|
|
|
|
| To attain synergistic effect or additive effect | 9(100) |
|
|
|
| The medical condition is refractory to the drug | 3(100) |
Fig 1Number of drug therapy problems among epileptic patients attending the ambulatory clinic of JMC, 2021.
Types and status of intervention provided for epileptic patients attending ambulatory clinic of JMC, 2021.
| Types and status of intervention | Frequency (n) | Percentage (%) |
|---|---|---|
| Counseling on adherence and ADR | 211 | 58.94 |
| Increasing dosage | 61 | 17 |
| Decreasing dosage | 50 | 13.97 |
| Addition of medication | 7 | 1.96 |
| Switching of medication | 27 | 7.54 |
| Discontinuation of medication | 2 | 0.56 |
| Intervention is fully accepted | 254 | 71 |
| Intervention is accepted with modification | 43 | 12.01 |
| Intervention is not accepted | 61 | 17.04 |
Bivariate and multivariate analysis of factors associated with DTPs among epileptic patients attending ambulatory clinic of JMC, 2021.
| Variables | DTP | Bivariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|---|
| Age in year | Yes | No | COR | P-value | AOR | P-value |
| 18–25 | 97(43.3) | 52(54.17) | 1 | 1 | ||
| 26–44 | 98(43.8) | 34(35.4) | 1.54(0.92–2.5) | 0.098 | 1.46(0.68–3.1) | 0.323 |
| ≥45 | 28(12.5) | 11(11.45) | 1.36(0.63–2.96) | 0.432 | 1.15(0.39–3.3) | 0.793 |
| Residency | ||||||
| Urban | 111(49.6) | 39(40.6) | 1 | 1 | ||
| Rural | 112(50.4) | 58(60.4) | 0.67(0.41–1.1) | 0.116 | 0.98(0.48–1.9) | 0.98 |
| Social drug use status | ||||||
| Yes | 42 | 22 | 0.77(0.43–1.39) | 0.394 | ------------------------ | --------------- |
| No | 182 | 74 | 1 | |||
| Medication fee | ||||||
| Free | 103(45.9) | 85(88.5) | 1 | 1 | ||
| Payment | 120(53.5) | 12(12.5) | 8.2(4.2–15) | <0.001 | 4.6(2.05–10.7) | <0.001 |
| Patient involvement | ||||||
| Actively involved | 56(25) | 61(63.5) | 1 | 1 | ||
| Poorly involved | 167(74.5) | 36(37.5) | 3.3(2–5.5) | <0.001 | 3.02(1.5–6.06) | 0.002 |
| Type of seizure | ||||||
| GTC | 158(70.5) | 63(65.6) | 1 | |||
| Focal | 19(8.4) | 6(6.25) | 1.2(0.48–3.3) | 0.635 | 0.47(0.12–1.9) | 0.293 |
| Unclassified | 46(20.5) | 28(29.1) | 0.65(0.37–1.13) | 0.134 | 0.41(0.11–1.7) | 0.24 |
| Follow up duration | ||||||
| 1–5 years | 49(21.8) | 32(33.33) | 1 | 1 | ||
| 6–10 years | 56(25) | 22(22.9) | 1.7(0.85–3.2) | 0.134 | 1.74(0.68–4.4) | 0.244 |
| >10 years | 118(52.6) | 43(44.8) | 1.8(1.02–3.15) | 0.043 | 1.6(0.71–3.78) | 0.243 |
| Seizure control status | ||||||
| Controlled | 82(36.6) | 86(89.58) | 1 | 1 | ||
| Uncontrolled | 141(62.9) | 11(11.45) | 13.4(6.7–26.6) | <0.001 | 10.9(4.9–24.2) | <0.001 |
| Quantity of AED | ||||||
| One | 96(42.85) | 64(66.7) | 1 | |||
| Two and above | 127(56.7) | 33(34.37) | 2.5(1.5–4.2) | <0.001 | 0.29(0.06–1.4) | 0.129 |
| Comorbidity | ||||||
| Yes | 61(27.23) | 8(8.3) | 4.2(1.9–9.1 | <0.001 | 1.73(0.61–4.8) | 0.297 |
| No | 162(72.3) | 89(92.7) | 1 | 1 | ||
| Total drugs | ||||||
| One | 75(33.48 | 62(64.58 | 1 | 1 | ||
| Two | 100(44.6) | 33(34.37) | 2.5(1.5–4.2) | 0.001 | 5.3(1.2–22.9) | 0.024 |
| Three and above | 48(21.42) | 2(2.08) | 19.8(4.6–24) | <0.001 | 31(3.8–50) | 0.001 |